1. Dattani MT, Robinson IC. The molecular basis for developmental disorders of the pituitary gland in man. Clin Genet. 2000; 57: 337-46.
2. Tsuda M, Takahashi S et al. CT and MR imaging of craniopharyngioma. Eur Radiol 1997; 7: 464:469
3. Carmel PW, Antunes JL, Chang CH. Craniopharyngioma in children. Neurosurgery 1982; 11: 382-9.
4. Bunin GR, Surawicz TS, Witman PA, Preston-Martin S, Davis F, Bruner JM. 1998 The descriptive epidemiology of craniopharyngioma. J Neurosurg. 89:547-551.
5. Atlas SW. Magnetic resonance imaging of the brain and spine. Raven Press, new York 1991.
6. Akimuta T, Karleda H, et al. Infrasellar craniopharyngioma. Neuroradiology 1989; 31: 180-3.
7. Hillman TH, Peyster RG, et al. Infrasellar craniopharyngiomas. J Comput Assist Tomogr 1988; 12: 702-4.
8. Lafferty AR, Chrousos GP. Pituitary tumors in children and adolescents. J Clin Endocrinol Metab 1999; 84: 4317-4323
9. Sklar CA. 1994 Craniopharyngioma: endocrine abnormalities at presentation. Pediatr Neurosurg. 21(Suppl 1):18-20.
10. Thomsett MJ, Conte FA, Kaplan SL, Grumbach MM. 1980 Endocrine and neurologic outcome in childhood craniopharyngioma: review of effect of treatment in 42 patients. J Pediatr. 97:728-735
11. Ghirardello S, Hopper N, Albanese A, Maghnie M.Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:413-21.
12. Muller HL. Chilhood craniopharyngioma. Horm Res 2008;69:193-202
13. Pusey E, Kortman KE, et al. MR of craniopharyngiomas: tumor delineation and characterization. AJNR 1987; 8: 439-444.
14. Braun IF, Pinto RS, Epstein F. Dense cystic craniopharyngiomas. AJNR 1982; 3: 139-141.
15. Garnett MR, Puget S, Grill J, Sainte-Rose C. Craniopharingioma. Orphanet Journal of Rare Disease 2007, 2:18
16. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg. 1999; 90:237-250.
17. Scott RM, Hetelekidis S, Barnes PD, Goumnerova L, Tarbell NJ. Surgery, radiation, and combination therapy in the treatment of childhood craniopharyngioma�a 20-year experience. Pediatr Neurosurg. 1994;21(Suppl 1):75-81.
18. Sanford RA. 1994 Craniopharyngioma: results of survey of the American Society of Pediatric Neurosurgery. Pediatr Neurosurg. 21(Suppl 1):39-43.
19. Hetelekidis S, Barnes PD, Tao ML, et al. 20-year experience in childhood craniopharyngioma. Int J Radiat Oncol Biol Phys. 1993; 27:189-195.
20. Sklar CA. Craniopharyngioma: endocrine sequelae of treatment. Pediatr Neurosurg. 1994; 21(Suppl 1):120-123.
21. Ahmet A, Blaser S, Stephens D, Guger S, Rutkas JT, Hamilton J. Weight gain in craniopharyngioma--a model for hypothalamic obesity. J Pediatr Endocrinol Metab. 2006; 19: 121-7
22. Muller HL, Muller-Stover S, Gebhardt U, Kolb R, Sorensen N, Handwerker G. Secondary narcolepsy may be a causative factor of increased daytime sleepiness in obese childhood craniopharyngioma patients.J Pediatr Endocrinol Metab. 2006; 19 Suppl 1:423-9.
23. Luu QT, Loredo LN, Archambeau JO, Yonemoto LT, Slater JM, Slater JD. Fractionated proton radiation treatment for pediatric craniopharyngioma: preliminary report. Cancer J. 2006 Mar-Apr;12: 155-9.
24. Sands SA, Milner JS, Goldberg Jet al. Quality of life and behavioral follow-up study of pediatric survivors of craniopharyngioma. J Neurosurg. 2005; 103 (4 Suppl): 302-11.
25. Steele CA, MacFarlane IA, Blair J, Cuthbertson DJ, Didi M, Mallucci C, Javadpour M, Daousi C. Pituitary adenomas in childhood, adolescence and young adulthood: presentation, management, endocrine and metabolic outcomes. Eur J Endocrinol. 2010 Oct;163(4):515-22. Epub 2010 Aug 4
26. Odom GL, Davis CH, Woodhall B. Brain tumors in children: Clinical analysis in 164 cases. Pediatrics 1956; 18:856-869.
27. Mindermann T, Wilson CB. Pediatric pituitary adenomas. Neurosurgery 1995; 36 :259-269.
28. Colao A, Loche S, Cappabianca P, de Divitiis E, Lombardi G. Pituitary adenomas in children and adolescents. Clinical presentation, diagnosis and therapeutical strategies. The Endocrinologist 2000; 10: 314-320.
29. Boop FA, Teo C, Pihoker K. Pediatric pituitary tumors. In: Krisht AF, Tindall GT (eds) Comprehensive management of pituitary disorders. Lippincott Williams & Wilkins, Hagerstown, 1999; pp 315-326.
30. Partington MD, Dudley HD, Laws ER, Scheithauer BW. Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurg 1994; 80 :209-216.
31. Ludecke DK, Herrmann HD, Schulte FJ. Special problems with neurosurgical treatment of hormone-secreting pituitary adenomas in children. Prog Exp Tumor Res 1987;30:362-70.
32. Gold EB. Epidemiology of pituitary adenomas. Epidemiol Rev 1981; 3: 163-183.
33. Haddad SF, VanGilder JC, Menezes AH. Pediatric pituitary tumors. Neurosurgery 1991; 29:509-514.
34. Kane LA, Leinung MC, Scheithauer BW, et al. Pituitary adenomas in childhood and adolescence. J Clin Endocrinol Metab 1994; 79: 1135-1140.
35. Artese R, D�Osvaldo DH, Molocznik I, et al. Pituitary tumors in adolescent patients. Neurol Res 1998;20:415-417.
36. Avramides A, Karapiperis A, Triantafyllidou E, Vayas S, Moshidou A, Vyzantiadis A. TSH-secreting pituitary macroadenoma in an 11-year-old girl. Acta Paediatr 1992;81:1058-1060.
37. Dyer EH, Civit E, Visot A, Delalande O, Derome P. Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery 1994; 34:207-212.
38. Maira G, Anile C. Pituitary adenomas in childhood and adolescence. Can J Neurol Sci 1990; 17: 83-87.
39. Richmond IL, Wilson CB. Pituitary adenomas in childhood and adolescence. J Neurosurg 1978; 49: 163-168.
40. Keil MF, Stratakis CA. Advances in the diagnosis, treatment, and molecular genetics of pituitary adenomas in childhood. US Endocinol.2009; 4(2): 81-85
41. Dissaneevate P, Warne GL. Hyperprolactinaemia and pituitary adenomas in adolescence. J Pediatr Endocrinol Metab 1998; 11:531-41.
42. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G 1998 Prolactinomas in children and adolescents.. Prolactinomas in children and adolescents. Clinical presentation and long term follow-up. J Clin Endocrinol Metab 1998; 83:2777-2780.
43. Cannav� S, Venturino M, Curto L, De Menis E, D'Arrigo C, Tita P, Billeci D, Trimarchi F. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol (Oxf). 2003; 58(4):519-27
44. Creemers LB, Zelissen PMJ, van�t Verlaat JW, Koppeschaar HPF. Prolactinoma and body weight: a retrospective study. Acta Endocrinol Scand 1991; 125:392-396
45. Delgrange E, Donkier J, Maiter D: Hyperprolactinemia as a reversible cause of weight gain in male patients?. Clin Endocrinol (Oxf) 1999;50:271-272.
46. Greenman Y, Torjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998;48:547-553
47. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006 Aug;27(5):485-534
48. Colao A, Loche S. Prolactinomas in children and adolescents. Endocr Dev. 2010;17:146-59. Epub 2009 Nov 24
49. Schlechte J, El-Khoury G, Kathol M, Walkner L. Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1987; 64; 1021-1026
50. Biller BMK, Baum HBA, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992; 75: 692-7
51. Di Somma C, Colao A, Di Sarno A, Klain M, Landi ML, Facciolli G, Pivonello R, Panza N, Salvatore M, Lombardi G. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998; 83: 807-813
52. Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G. Prolactinomas in children and adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol 2000; 52: 319-328
53. Di Sarno A, Rota F, Auriemma R, De Martino MC, Lombardi G, Colao A. An evaluation of patients with hyperprolactinemia: have dynamic tests had their day?. J Endocrinol Invest 2003;26(7suppl):39-47
54. Cavaco B, Leite V, Santos MA, et al. Some forms of big big prolactin behave as a complex of monomeric with an immunoglobulin G in patients with macroprolactinoma or prolactinomas. J Clin Endocrinol Metab 1995;80:3507-3512
55. Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S: Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer 2008;15:905-915
56. Tyson D, Reggiardo D, Sklar C, David R. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child 1993; 147:1057-1061
57. Blackwell RE, Younger BJ. Long-term medical therapy and follow up of pediatric adolescent patients with prolactin-secreting macroadenomas. Fertil Steril 1986; 45 :713-716
58. Howlett TA, Wass JA, Grossman A, Plowman PN, Charlesworth M, Touzel R, Rees LH, Savage MO, Besser GM. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy. Clin Endocrinol. 1989; 30:131-140
59. Dalzell GW, Atkinson AB, Carson PJ, Sheridan B. Normal growth and pubertal development during bromocriptine treatment for a prolactin-secreting pituitary macroadenoma. Clin Endocrinol 1987; 26:169-172
60. Knoepfelmacher M, Gomes MC, Melo ME, Mendonca BB. Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma. Pituitary 2004;7(2):83-7
61. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G  Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003;349:2023-33
62. Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ, Meacham LR. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma. J Pediatr Hematol Oncol 2005;27:326-329
63. Colao A, Galderisi M, Di Sarno A, Pardo M, Gaccione M, D'Andrea M, Guerra E, Pivonello R, Lerro G, Lombardi G. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008;93:3777-3784
64. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19:647-672
65.  Magiakou MA, Mastorakos G, Gomez MT, Rose SR, Chrousos GP. Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing's disease before and after surgical cure. J Clin Endocrinol Metab 1994; 78:131-137
66. Savage MO, Chan LF, Grossman AB, Storr HL. Work-up and management of paediatric Cushing's syndrome. Curr Opin Endocrinol Diabetes Obes. 2008 Aug;15(4):346-51
67. Baron J, Klein KO, Colli MJ, et al. Catch-up growth after glucocorticoid excess: a mechanism intrinsic to the growth plate. Endocrinology 1994; 135:1367-1371
68. Magiakou MA, Mastorakos G, Oldfield EH, et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med 1994; 331:629-636
69. Weber A, Trainer PJ, Grossman AB, et al. Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clin Endocrinol 1995; 43:19-28
70. Devoe DJ, Miller WL, Conte FA, et al. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 1997; 82:3196-3202
71. Leong GM, Mercado-Asis LB, Reynolds JC, Hill SC, Oldfield EH, Chrousos GP. The effect of Cushing's disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J Clin Endocrinol Metab 1996; 81:1905-1911
72. Dempster D, Arlot M, Meunier P. Mean wall thickness and formation period of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif Tissue Int 1983; 35:410-417
73. Di Somma C, Pivonello R, Loche S, Faggiano A, Marzullo P, Di Sarno A, Klain M, Salvatore M, Lombardi G, Colao A. Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood onset disease. Clin Endocrinol 2002; 56: 153-8
74. Di Somma C, Pivonello R, Loche S, Faggiano A, Klain M, Salvatore M, Lombardi G, Colao A. Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease. Clin Endocrinol 2003; 58(3):302-8
75. Lodish MB, Hsiao HP, Serbis A, Sinaii N, Rothenbuhler A, Keil MF, Boikos SA, Reynolds JC, Stratakis CAEffects of Cushing disease on bone mineral density in a pediatric population. J Pediatr. 2010 Jun;156(6):1001-5
76. Bressot C, Meunier P, Chapuy M, Lejeune E, Edouard C, Darby A. Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Relat Res 1979; 1:303-311
77. Delany A, Gabbitas B, Canalis E. Cortisol down-regulates osteoblast α1 (I) procollagen mRNA by trascriptional and post-trascriptional mechanism. J Cell Biochem 1995; 57:488-494
78. Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996; 81: 3441-3447
79. Khanine V, Fournier JJ, Requeda E, Luton JP, Simon F, Crouzet J. Osteoporotic fractures at presentation of Cushing's disease: two case reports and a literature review. Joint Bone Spine 2000;67:341-5
80. Buzi F, Corna A, Pilotta A, et al. Loperamide test: a simple and highly specific screening test for hypercortisolism in children and adolescents. Acta Paediatr 1997; 66:1177-1180
81. Yaneva M, Monsier-Pudar H, Dugue M, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 2004;89(7):3345-51
82. Kunvar S, Wilson CB. Pediatric pituitary adenomas. J Clin Endocrinol Metab 1999; 84:4385-4389
83. Colao A, Faggiano A, Pivonello R, Pecori Giraldi F, Cavagnini F, Lombardi G, and The Study Group of the Italian Endocrinology Society on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis. Inferior petrosal sinus sampling in the differential diagnosis of Cushing's syndrome: Results of an Italian multicentre study. Eur J Endocrinol 2001; 144: 499-507
84. Lienhardt A, Grossman AB, Dacie JE, et al. Relative contributions of inferior petrosal sinus sampling and pituitary imaging in the investigation of children and adolescents with ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2001; 86:5711-5714
85. Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991; 325:897-905
86. Styne DM, Grumbach MM, Kaplan SA, Wilson CB, Conte FA. Treatment of Cushing's disease in childhood and adolescence by transphenoidal microadenomectomy. N Engl J Med 1984; 310:889-893
87. Buchfelder M, Fahlbusch R. Neurosurgical treatment of Cushing's disease in children and adolescents. Acta Neurochirurg 1985; suppl 35:101-103
88. Fahlbush R, Honegger J, Buchfelder M. Neurosurgical management of Cushing's disease in children. In: Savage MO, Bourguignon JP, Grossman AB (Eds), Frontiers in Pediatric Neuroendocrinology 1994; 68-72
89. Massoud AF, Powell M, Williams RA, Hindmarsh PC, Brook CGD. Transsphenoidal surgery for pituitary tumours. Arch Dis Child 1997; 76:398-404
90. Leinung MC, Kane LA, Scheithauer BW, Carpenter PC, Laws ER Jr, Zimmerman D. Long term follow-up of transsphenoidal surgery or the treatment of Cushing's disease in childhood. J Clin Endocrinol Metab 1995; 80:2475-2479
91. Storr HL, Afshar F, Matson M, et al. Factors influencing cure by trans-sphenoidal selective adenomectomy in paediatric Cushing's disease. Eur J Endocrinol 2005; 152: 825-33
92. Clayton RN, Stewart PM, Shalet SM, Wass JA 1999 Pituitary surgery for acromegaly. Should be done by specialists. BMJ 319:588-589
93. Magiakou MA, Mastorakos G, Chrousos GP. Final stature in patients with endogenous Cushing's syndrome. J Clin Endocrinol Metab 1994; 79:1082-1085.
94. Johnston LB, Grossman AB, Plowman PN, Besser GM, Savage MO. Normal final height and apparent cure after pituitary irradiation for Cushing's disease in childhood: long-term follow-up of anterior pituitary function. Clin Endocrinol 1998; 48:663-667.
95. Lebrethon MC, Grossman AB, Afshar F, Plowman PN, Besser GM, Savage MO. Linear growth and final height after treatment for Cushing's disease in childhood. J Clin Endocrinol Metab 2000; 85: 3262-5
96. Davies JH, Storr HL, Davies K, Monson JP, Besser GM, Afshar F, Plowman PN, Grossman AB, Savage MO.Final adult height and body mass index after cure of paediatric Cushing's disease. Clin Endocrinol (Oxf). 2005; 62: 466-72
97. Friedman RB, Oldfield EH, Nieman LH, et al. Repeat trans-sphenoidal surgery for Cushing's disease. J Neurosurg 1989; 71:520-527
98. Estrada J, Boronat M, Mielgo M, et al. The long term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 1997; 336: 172-177
99. Jennings AS, Liddle GW, Orth DN. Results of treating childhood Cushing's disease with pituitary irradiation. N Engl J Med 1977; 297:957-962
100. Greening JE, Brain CE, Perry LA, et al. Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing's disease. Horm Res. 2005; 64: 140-3
101. Merke DP, Giedd JN, Keil MF, et al. Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome. J Clin Endocrinol Metab. 2005; 90: 2531-6
102. Colao A, Lombardi G. GH and PRL excess. Lancet 1998; 352: 1455-1461
103. Eugster EA, Pescovitz OH. Gigantism. J Clin Endocrinol Metab 1999; 84: 4379-3484.
104. Sotos JF. Overgrowth, section II. Clin Pediatr. 1996; 35: 579-590
105. Whitehead EM, Shalet SM, Davies D, Enoch BA, Price DA, Beardwell CG. Pituitary gigantism: a disabling condition. Clin Endocrinol. 1982; 17:271-277
106. Colao A, Merola B, Ferone D, Lombardi G. Acromegaly. J Clin Endocrinol Metab 1997;82:2777-2781
107. Melmed S. Acromegaly and cancer: not a problem. J Clin Endocrinol Metab 2001; 86: 2929-2934
108. Jenkins PJ, Besser M. Acromegaly and cancer: a problem. J Clin Endocrinol Metab 2001; 86: 2935-2941
109. Barkan A. Acromegalic arthropathy and sleep apnea. J Endocrinol 1997;155:S41-44
110. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004; 25: 102-152
111. Colao A, Pivonello R, Di Somma C, Tauchmanov� L, Savastano S, Lombardi G. Growth hormone excess with onset in adolescence: clinical appearance and long-term treatment outcome Clin Endocrinol (Oxf). 2007 May;66(5):714-22
112. Bondanelli M, Bonadonna S, Ambrosio MR, et al. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Metabolism. 2005; 54: 1174-80
113. Lamberts SWJ, van der Lely AJ, de Herder WW. Clinical and medical diagnosis of acromegaly. Metabolism 1995;44(suppl.1):15-17
114. Blumberg DL, Sklar CA, David R, Rothenberg S, Bell J. Acromegaly in an infant. Pediatrics 1989;83:998-1002
115. Kaltsas GA, Mukherjee JJ; Jenkins PJ, et al. Mestrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999; 84: 2731-2735
116. Alvi NS, Kirk JM. Pituitary gigantism causing diabetic ketoacidosis. J Pediatr Endocrinol Metab 1999; 12: 907-909
117. Giustina A, Barkan A, Casanueva FF, et al. 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
118. de Herder WW, van der Lely AJ, Janssen JAMJL, et al. IGFBP-3 is a poor parameter for assessment of clinical activity in acromegaly. Clin Endocrinol 1995; 43:501-515
119. Marzullo P, Di Somma C, Pratt KL, et al.Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 2001;86:3001-8
120. Ng LL, Chasalow FI, Escobar O, Blethen SL. Growth hormone isoforms in a girl with gigantism. J Pediatr Endocrinol Metab 1999; 12: 99-106
121. Chapman IM, Hartan ML, Straume M, Johnson ML, Veldhuis JD, Thorner MO. Enhanced sensitivity growth hormone (GH) chemiluminescence assay reveals lower postglucose nadir GH concentrations in men than in women. J Clin Endocrinol Metab 1994;78:1312-1319
122. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol 1998; 49: 653-657
123. Ahmed S, Eldsheikh, Stratton IM, Page RC, Adams, CB, Wass JA. Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience. Clin Endocrinol 1999; 50: 561-567
124. Yamada S, Aibat T, Takada K, et al. Retrospective analysis of long-term surgical results in acromegaly: preoperative and post-operative factors predicting outcome. Clin Endocrinol 1996;45:291-298
125. Sheaves R, Jenkins P, Blackburn P, et al. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 1996;45:407-13
126. Abe T, Tara LA, L'decke DK. Growth hormone-secreting pituitary adenomas in childhood and adolescence: features and results of transnasal surgery. Neurosurgery 1999; 45: 1-10
127. Ferone D, Colao A, van der Lely A-J, Lamberts SWJ. Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs 2000; 17: 81-92
128. Gelber SJ, Heffez DS, Donohoue PA. Pituitary gigantism caused by growth hormone excess from infancy. J Pediatr 1992; 120: 931-4
129. Yoshida T, Shimatsu A, Sakane N, Hizuka N, Horikawa R, Tanaka T. Growth hormone (GH) secretory dynamics in a case of acromegalic gigantism associated with hyperprolactinemia: nonpulsatile secretion of GH may induce elevated insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels. J Clin Endocrinol Metab 1996; 81: 310-3
130. Eastman RC, Gorden P, Glatstein E, Roth J. Radiation therapy for acromegaly. Endocrinol Metab Clin North Am 1992;21:693-712
131. Barkan AL, Halasz I, Dornfeld KJ, Jaffe CA, Friberg RD, Chandler WF, Sandler HM.. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab 1997;82:3187-3191.
132. Thalassinos NC, Tsagarakis S, Ioannides G, Tzavara I, Papavasiliou C. Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in safe GH levels in acromegaly: a long-term follow-up study. Eur J Endocrinol 1998;138:160-163.
133. Epaminonda P, Porretti S, Cappiello V, Beck-Peccoz P, Faglia G, Arosio M. Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clin Endocrinol (Oxf) 2001; 55: 183-9
134. Gutt B, Hatzack C, Morrison K, Pollinger B, Schopohl J. Conventional pituitary irradiation is effective in normalising plasma IGF-I in patients with acromegaly.Eur J Endocrinol. 2001; 144: 109-16
135. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992;13:221-235
136. Moran A, Pescovitz OH. Long-term treatment of gigantism with combination octreotide and bromocriptine in a child with McCune-Albright syndrome. Endocr J 1994; 2:111-113
137. Maheshwari HG, Prezant TR, Herman-Bonert V, Shahinian H, Kovacs K, Melmed S.Long-acting peptidomimergic control of gigantism caused by pituitary acidophilic stem cell adenoma. J Clin Endocrinol Metab 2000; 85: 3409-16
138. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000; 342:1171-1177
139. van der Lely AJ, Hutson RK, Trainer PJ, et al. Long term treatment of acromegaly with pegvisomant, a growth hormone antagonist. Lancet 2001; 358:1754-1759
140. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ., Lombardi G. Efficacy of 12-months of treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high dose somatostatin analog treatment: effect on IGF-I levels, tumour mass, hypertension and glucose tolerance. European Journal of Endocrinology2006, 154, 467-477
141. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol. 2005;153: 195-201
142. Beck-Peccoz P, Bruckner-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610-638.
143. Fukuda T, Yokoyama N, Tamai M, et al. Thyrotropin secreting pituitary adenoma effectively treated with octreotide. Intern Med 1998;37:1027-1030
144. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormone-secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236-240
145. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol 1994;40:421-428
146. Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P.Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000; 85: 1487-1491
147. Freda PU, Wardlaw SL. Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 1999;84:3859-3866
148. Katnelson L, Alexander JM, Klibanski A. Clinically nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 1993;76:1089-1094
149. Abe T, L'decke DK, Saeger W. Clinically nonsecreting pituitary adenomas in childhood and adolescence. Neurosurgery 1998; 42: 744-751
150. Laws ER Jr. Transsphenoidal approach to lesions in and about the sella turcica. In Schmidek HH, Sweet WH (eds): Operative neurosurgical techniques: indications, methods and results. Grune & Stratton, Orlando, 1, 1995; pp. 283-292
151. Jho HD, Carrau RL. Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 1997;87:44-51
152. Cappabianca P, Alfieri A, Colao A, Ferone D, Lombardi G, de Divitiis E. Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. Skull Base Surg 1999; 9:109-117
153. Cappabianca P, Alfieri A, Colao A, Cavallo LM, Fusco M, Peca C, Lombardi G, de Divitiis E Endoscopic endonasal transsphenoidal surgery in recurrent and residual pituitary adenomas: technical note. Minim Invasive Neurosurg 2000; 43: 38-43
154. Cappabianca P, de Divitiis E, Alfieri A, Cavallo LM. The role of the endoscopic transsphenoidal approach in pediatric neurosurgery. Child's Nervous Syst 2000; 16: 692-6
155. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton MI. Hypopituitarism following external radiotherapy for pituitary tumors in adults. QJ Med New Series. 1989; 70:145
156. Colao A, Cerbone G, Cappabianca P, et al. Effect of surgery and radiotherapy in visual and endocrine function in nonfunctioning pituitary adenomas. J Endocrinol Invest 1998; 21:284-290
157. Turner HE, Stratton IM, Byrne JV, Adams CB, Wass JA. Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clin Endocrinol (Oxf) 1999; 51: 281-284
158. Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, Faggiano A, Merola B, Lombardi G. New medical approaches in pituitary adenomas. Horm Res 2000; 53:76-87
159. Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi GHormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-Methoxybenzamide. Clin Endocrinol 2000; 52:437-445
160. Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, Colao A, Annunziato L, Lombardi G. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004; 89: 1674-83